NS Partners Ltd cut its stake in Celgene Corporation (NASDAQ:CELG) by 52.2% during the first quarter, Holdings Channel reports. The firm owned 19,116 shares of the biopharmaceutical company’s stock after selling 20,834 shares during the period. NS Partners Ltd’s holdings in Celgene Corporation were worth $2,379,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the company. Motco boosted its stake in shares of Celgene Corporation by 306.9% in the first quarter. Motco now owns 822 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 620 shares during the period. Harel Insurance Investments & Financial Services Ltd. purchased a new position in Celgene Corporation during the first quarter valued at approximately $118,000. Carroll Financial Associates Inc. raised its position in Celgene Corporation by 70.9% in the first quarter. Carroll Financial Associates Inc. now owns 964 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 400 shares in the last quarter. Oakworth Capital Inc. raised its position in Celgene Corporation by 60.9% in the first quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 412 shares in the last quarter. Finally, Mitsubishi UFJ Securities Holdings Co. Ltd. raised its position in Celgene Corporation by 47.5% in the first quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 380 shares in the last quarter. Institutional investors and hedge funds own 78.41% of the company’s stock.

Celgene Corporation (NASDAQ:CELG) traded up 0.39% on Friday, hitting $130.88. 1,019,018 shares of the company were exchanged. The company has a market capitalization of $102.39 billion, a price-to-earnings ratio of 40.53 and a beta of 1.89. The stock has a 50 day moving average of $134.23 and a 200 day moving average of $124.17. Celgene Corporation has a 52 week low of $96.93 and a 52 week high of $139.00.

Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The company had revenue of $3.27 billion during the quarter, compared to analyst estimates of $3.23 billion. During the same quarter last year, the firm posted $1.44 earnings per share. The firm’s revenue was up 18.7% on a year-over-year basis. Analysts predict that Celgene Corporation will post $7.32 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/08/11/ns-partners-ltd-has-2-38-million-stake-in-celgene-corporation-nasdaqcelg.html.

Several equities analysts have commented on CELG shares. Leerink Swann raised shares of Celgene Corporation from a “market perform” rating to an “outperform” rating and raised their target price for the company from $94.42 to $150.00 in a report on Friday, June 16th. They noted that the move was a valuation call. Goldman Sachs Group, Inc. (The) reissued a “sell” rating and issued a $98.00 target price (up from $93.00) on shares of Celgene Corporation in a report on Wednesday, May 17th. William Blair reissued an “outperform” rating on shares of Celgene Corporation in a report on Monday, June 26th. BTIG Research lowered shares of Celgene Corporation from a “buy” rating to a “neutral” rating and raised their target price for the company from $96.93 to $131.70 in a report on Friday, June 30th. Finally, Canaccord Genuity set a $156.00 target price on shares of Celgene Corporation and gave the company a “buy” rating in a report on Monday, May 22nd. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, twenty-two have assigned a buy rating and one has issued a strong buy rating to the stock. Celgene Corporation presently has a consensus rating of “Buy” and an average price target of $147.00.

In related news, insider Robert J. Hugin sold 175,970 shares of the firm’s stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $134.14, for a total value of $23,604,615.80. Following the completion of the sale, the insider now owns 1,033,909 shares of the company’s stock, valued at $138,688,553.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gilla Kaplan sold 7,500 shares of the firm’s stock in a transaction on Wednesday, August 2nd. The stock was sold at an average price of $134.52, for a total value of $1,008,900.00. Following the completion of the sale, the director now directly owns 76,301 shares of the company’s stock, valued at approximately $10,264,010.52. The disclosure for this sale can be found here. Insiders sold 235,255 shares of company stock valued at $31,377,042 in the last ninety days. 0.95% of the stock is currently owned by insiders.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.